Your request to link to rcsb for WD repeat-containing protein 5 (WDR5)

---

• 2CNX: wdr5 and histone h3 lysine 4 dimethyl complex at 2.1 angstrom (10.1038/NSMB1119 )
• 2CO0: wdr5 and unmodified histone h3 complex at 2.25 angstrom (10.1038/NSMB1119 )
• 2G99: structural basis for the specific recognition of methylated histone h3 lysine 4 by the wd-40 protein wdr5
• 2G9A: structural basis for the specific recognition of methylated histone h3 lysine 4 by the wd-40 protein wdr5
• 2GNQ: structure of wdr5 (10.1038/SJ.EMBOJ.7601316 )
• 2H13: crystal structure of wdr5/histone h3 complex (10.1038/NSMB1116 )
• 2H14: crystal of wdr5 (apo-form) (10.1038/NSMB1116 )
• 2H68: histone h3 recognition and presentation by the wdr5 module of the mll1 complex (10.1038/NSMB1119 )
• 2H6K: histone h3 recognition and presentation by the wdr5 module of the mll1 complex (10.1038/NSMB1119 )
• 2H6N: histone h3 recognition and presentation by the wdr5 module of the mll1 complex (10.1038/NSMB1119 )
• 2H6Q: histone h3 recognition and presentation by the wdr5 module of the mll1 complex (10.1038/NSMB1119 )
• 2H9L: wdr5delta23 (10.1038/SJ.EMBOJ.7601316 )
• 2H9M: wdr5 in complex with unmodified h3k4 peptide (10.1038/SJ.EMBOJ.7601316 )
• 2H9N: wdr5 in complex with monomethylated h3k4 peptide (10.1038/SJ.EMBOJ.7601316 )
• 2H9P: wdr5 in complex with trimethylated h3k4 peptide (10.1038/SJ.EMBOJ.7601316 )
• 2O9K: wdr5 in complex with dimethylated h3k4 peptide (10.1038/SJ.EMBOJ.7601316 )
• 2XL2: wdr5 in complex with an rbbp5 peptide recruited to novel site (10.1074/JBC.M110.159921 )
• 2XL3: wdr5 in complex with an rbbp5 peptide and histone h3 peptide (10.1074/JBC.M110.159921 )
• 3EG6: structure of wdr5 bound to mll1 peptide (10.1074/JBC.C800164200 )
• 3EMH: structural basis of wdr5-mll interaction (10.1074/JBC.M806900200 )
• 3MXX: crystal structure of wdr5 mutant (s62a) (10.1021/BI101321Y )
• 3N0D: crystal structure of wdr5 mutant (w330f) (10.1021/BI101321Y )
• 3N0E: crystal structure of wdr5 mutant (w330y) (10.1021/BI101321Y )
• 3P4F: structural and biochemical insights into mll1 core complex assembly and regulation. (10.1016/J.STR.2010.09.022 )
• 3PSL: fine-tuning the stimulation of mll1 methyltransferase activity by a histone h3 based peptide mimetic (10.1096/FJ.10-171959 )
• 3SMR: crystal structure of human wd repeat domain 5 with compound (10.1042/BJ20121280 )
• 3UR4: crystal structure of human wd repeat domain 5 with compound (10.1042/BJ20121280 )
• 3UVK: crystal structure of wdr5 in complex with the wdr5-interacting motif of mll2 (10.1093/NAR/GKR1235 )
• 3UVL: crystal structure of wdr5 in complex with the wdr5-interacting motif of mll3 (10.1093/NAR/GKR1235 )
• 3UVM: crystal structure of wdr5 in complex with the wdr5-interacting motif of mll4 (10.1093/NAR/GKR1235 )
• 3UVN: crystal structure of wdr5 in complex with the wdr5-interacting motif of set1a (10.1093/NAR/GKR1235 )
• 3UVO: crystal structure of wdr5 in complex with the wdr5-interacting motif of set1b (10.1093/NAR/GKR1235 )
• 4A7J: symmetric dimethylation of h3 arginine 2 is a novel histone mark that supports euchromatin maintenance (10.1038/NSMB.2209 )
• 4CY1: crystal structure of the kansl1-wdr5 complex. (10.1101/GAD.240200.114 )
• 4CY2: crystal structure of the kansl1-wdr5-kansl2 complex. (10.1101/GAD.240200.114 )
• 4CY3: crystal structure of the nsl1-wds complex. (10.1101/GAD.240200.114 )
• 4CY5: crystal structure of the nsl1-wds-nsl2 complex. (10.1101/GAD.240200.114 )
• 4ERQ: x-ray structure of wdr5-mll2 win motif peptide binary complex (10.1074/JBC.M112.364125 )
• 4ERY: x-ray structure of wdr5-mll3 win motif peptide binary complex (10.1074/JBC.M112.364125 )
• 4ERZ: x-ray structure of wdr5-mll4 win motif peptide binary complex (10.1074/JBC.M112.364125 )
• 4ES0: x-ray structure of wdr5-setd1b win motif peptide binary complex (10.1074/JBC.M112.364125 )
• 4ESG: x-ray structure of wdr5-mll1 win motif peptide binary complex (10.1074/JBC.M112.364125 )
• 4EWR: x-ray structure of wdr5-setd1a win motif peptide binary complex (10.1074/JBC.M112.364125 )
• 4GM3: crystal structure of human wd repeat domain 5 with compound mm-101 (10.1021/JA306028Q )
• 4GM8: crystal structure of human wd repeat domain 5 with compound mm-102 (10.1021/JA306028Q )
• 4GM9: crystal structure of human wd repeat domain 5 with compound mm-401
• 4GMB: crystal structure of human wd repeat domain 5 with compound mm-402 (10.1021/ACS.JMEDCHEM.6B01796 )
• 4IA9: crystal structure of human wd repeat domain 5 in complex with 2- chloro-4-fluoro-3-methyl-n-[2-(4-methylpiperazin-1-yl)-5- nitrophenyl]benzamide (10.1021/ML300467N )
• 4O45: wdr5 in complex with influenza ns1 c-terminal tail (10.1038/NCOMMS4952 )
• 4QL1: crystal structure of human wdr5 in complex with compound oicr-9429 (10.1038/NCHEMBIO.1859 )
• 4QQE: crystal structure of wdr5, wd repeat domain 5 in complex with compound sgc-ds-mt-0345
• 4Y7R: crystal structure of wdr5 in complex with myc mbiiib peptide (10.1016/J.MOLCEL.2015.02.028 )
• 5EAL: crystal structure of human wdr5 in complex with compound 9h
• 5EAM: crystal structure of human wdr5 in complex with compound 9o (10.1021/ACS.JMEDCHEM.5B01630 )
• 5EAP: crystal structure of human wdr5 in complex with compound 9e (10.1021/ACS.JMEDCHEM.5B01630 )
• 5EAR: crystal structure of human wdr5 in complex with compound 9d (10.1021/ACS.JMEDCHEM.5B01630 )
• 5M23: modulation of mll1 methyltransferase activity (10.1039/C7SC00137A )
• 5M25: modulation of mll1 methyltransferase activity (10.1039/C7SC00137A )
• 5SXM: wdr5 in complex with mll win motif peptidomimetic (10.1074/JBC.M116.752626 )
• 5VFC: wdr5 bound to inhibitor mm-589 (10.1021/ACS.JMEDCHEM.6B01796 )
• 6BYN: crystal structure of wdr5-mb(s4) monobody complex (10.1038/S41589-018-0099-Z )
• 6D9X: discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design (10.1021/ACS.JMEDCHEM.8B00375 )
• 6DAI: discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design (10.1021/ACS.JMEDCHEM.8B00375 )
• 6DAK: discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design (10.1021/ACS.JMEDCHEM.8B00375 )
• 6DAR: discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design (10.1021/ACS.JMEDCHEM.8B00375 )
• 6DAS: discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design (10.1021/ACS.JMEDCHEM.8B00375 )
• 6DY7: wdr5 in complex with a win site inhibitor (10.1016/J.CELREP.2019.02.047 )
• 6DYA: wdr5 in complex with a win site inhibitor (10.1016/J.CELREP.2019.02.047 )
• 6E1Y: discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design (10.1016/J.CELREP.2019.02.047 )
• 6E1Z: displacement of wdr5 from chromatin by a pharmacological win site inhibitor with picomolar affinity (10.1016/J.CELREP.2019.02.047 )
• 6E22: displacement of wdr5 from chromatin by a pharmacological win site inhibitor with picomolar affinity (10.1016/J.CELREP.2019.02.047 )
• 6E23: displacement of wdr5 from chromatin by a pharmacological win site inhibitor with picomolar affinity (10.1016/J.CELREP.2019.02.047 )
• 6IAM: modulating protein-protein interactions with visible light peptide backbone switches (10.1002/CBIC.201800737 )
• 6KIU: cryo-em structure of human mll1-ubncp complex (3.2 angstrom) (10.1038/S41586-019-1528-1 )
• 6KIV: cryo-em structure of human mll1-ubncp complex (4.0 angstrom) (10.1038/S41586-019-1528-1 )
• 6KIW: cryo-em structure of human mll3-ubncp complex (4.0 angstrom) (10.1038/S41586-019-1528-1 )
• 6KIX: cryo-em structure of human mll1-ncp complex, binding mode1 (10.1038/S41586-019-1528-1 )
• 6KIZ: cryo-em structure of human mll1-ncp complex, binding mode2 (10.1038/S41586-019-1528-1 )
• 6OFZ: crystal structure of human wdr5 (10.1021/ACS.BIOCHEM.0C00035 )
• 6OI0: crystal structure of human wdr5 in complex with l-arginine (10.1021/ACS.BIOCHEM.0C00035 )
• 6OI1: crystal structure of human wdr5 in complex with monomethyl l-arginine (10.1021/ACS.BIOCHEM.0C00035 )
• 6OI2: crystal structure of human wdr5 in complex with symmetric dimethyl-l- arginine (10.1021/ACS.BIOCHEM.0C00035 )
• 6OI3: crystal structure of human wdr5 in complex with monomethyl h3r2 peptide (10.1021/ACS.BIOCHEM.0C00035 )
• 6PG3: wdr5delta23 bound to (2-butyl-1h-imidazol-4-yl)methanol (10.1063/1.5122849 )
• 6PG4: wdr5delta32 bound to (2-methyl-1h-imidazol-4-yl)methanol (10.1063/1.5122849 )
• 6PG5: wdr5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1h-imidazol-2-yl) butyl)carbamate (10.1063/1.5122849 )
• 6PG6: wdr5delta23 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl) acetamide (10.1063/1.5122849 )
• 6PG7: wdr5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1h-imidazol-4-yl) methanol (10.1063/1.5122849 )
• 6PG8: wdr5delta23 bound to (2-(3-phenylpropyl)-1h-imidazol-4-yl)methanol (10.1063/1.5122849 )
• 6PG9: wdr5delta23 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl) benzamide (10.1063/1.5122849 )
• 6PGA: wdr5delta32 bound to methyl (4-(4-(hydroxymethyl)-1h-imidazol-2-yl) butyl)carbamate (10.1063/1.5122849 )
• 6PGB: wdr5delta32 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl)- 2-phenylacetamide (10.1063/1.5122849 )
• 6PGC: wdr5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1h-imidazol-2- yl)butyl)carbamate (10.1063/1.5122849 )
• 6PGD: wdr5delta32 bound to peptidomimetic (10.1063/1.5122849 )
• 6PGE: wdr5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1h-imidazol-2-yl) propanoate (10.1063/1.5122849 )
• 6PGF: wdr5delta32 bound to n-(4-(4-(hydroxymethyl)-1h-imidazol-2-yl)butyl) acrylamide (10.1063/1.5122849 )
• 6PWV: cryo-em structure of mll1 core complex bound to the nucleosome 18-mar-20 6pwv 1 title (10.1038/S41467-019-13550-2 )
• 6PWW: cryo-em structure of mll1 in complex with rbbp5 and wdr5 bound to the nucleosome (10.1038/S41467-019-13550-2 )
• 6U5M: discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction (10.1021/ACS.JMEDCHEM.9B01411 )
• 6U5Y: discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction (10.1021/ACS.JMEDCHEM.9B01411 )
• 6U6W: discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction (10.1021/ACS.JMEDCHEM.9B01411 )
• 6U80: discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction (10.1021/ACS.JMEDCHEM.9B01411 )
• 6U8B: discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction (10.1021/ACS.JMEDCHEM.9B01411 )
• 6U8L: discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction (10.1021/ACS.JMEDCHEM.9B01411 )
• 6U8O: discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction (10.1021/ACS.JMEDCHEM.9B01411 )
• 6UCS: discovery and structure-based optimization of potent and selective wdr5 inhibitors containing a dihydroisoquinolinone bicyclic core (10.1021/ACS.JMEDCHEM.9B01608 )
• 6UFX: wd repeat-containing protein 5 complexed with n-[(3,5- dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2e)-2-imino-3-methyl-2,3- dihydro-1h-imidazol-1-yl]methyl}-2'-methyl[1,1'-biphenyl]-3- carboxamide (compound 13) (10.1021/ACS.JMEDCHEM.9B01608 )
• 6UHY: wdr5 in complex with myc site fragment inhibitor (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UHZ: wdr5 in complex with myc site fragment inhibitor (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UIF: discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the wdr5-myc interaction (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UIK: discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the wdr5-myc interaction (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UJ4: discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the wdr5-myc interaction (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UJH: discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the wdr5-myc interaction (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UJJ: discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the wdr5-myc interaction (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UJL: discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the wdr5-myc interaction (10.1021/ACS.JMEDCHEM.0C00224 )
• 6UOZ: discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the wdr5-myc interaction (10.1021/ACS.JMEDCHEM.0C00224 )
• 6W5I: cryo-em structure of mll1 in complex with rbbp5, wdr5, set1, and ash2l bound to the nucleosome (class01)
• 6W5M: cryo-em structure of mll1 in complex with rbbp5, wdr5, set1, and ash2l bound to the nucleosome (class02)
• 6W5N: cryo-em structure of mll1 in complex with rbbp5, wdr5, set1, and ash2l bound to the nucleosome (class05)
• 6WJQ: crystal structure of wdr5 in complex with the win peptide of pdpk1
• 7AXP: structural characterisation of wdr5:cs-vip8 interaction in cis state 2
• 7AXQ: structure of the cryo-trapped wdr5:cs-vip8 cocrystal after illumination at 405 nm and 180 k
• 7AXS: structural characterisation of wdr5:cs-vip8 interaction in cis state 1
• 7AXU: structure of wdr5:cs-vip8 cocrystal after illumination in situ
• 7AXX: structure of wdr5:cs-vip8 crystal after illumination at 405 nm and room temperature
• 7BCY: x-ray structure of wdr5delta24 bound to the kaposi's sarcoma herpesvirus lana win motif peptide (10.1093/NAR/GKAB1094 )
• 7BED: x-ray structure of wdr5 bound to the wdr5 win motif peptide (10.1093/NAR/GKAB1094 )
• 7CFP: crystal structure of wdr5 in complex with a h3q5ser peptide
• 7CFQ: crystal structure of wdr5 in complex with h3k4me3q5ser peptide
• 7DNO: characterization of peptide ligands against wdr5 isolated using phage display technique
• 7JTO: crystal structure of protac ms33 in complex with the wd repeat- containing protein 5 and pvhl:elonginc:elonginb (10.1126/SCITRANSLMED.ABJ1578 )
• 7JTP: crystal structure of protac ms67 in complex with the wd repeat- containing protein 5 and pvhl:elonginc:elonginb (10.1126/SCITRANSLMED.ABJ1578 )
• 7MBM: cryo-em structure of mll1-ncp (h3k4m) complex, mode01 (10.1021/ACS.BIOCHEM.1C00603 )
• 7MBN: cryo-em structure of mll1-ncp (h3k4m) complex, mode02 (10.1021/ACS.BIOCHEM.1C00603 )
• 7Q2J: quaternary complex of human wdr5 and pvhl:elonginc:elonginb bound to protac homer
• 7U9Y: wdr5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1h-imidazol-1-yl) methyl)-5-(1-methyl-3-(trifluoromethyl)-1h-pyrazol-4-yl)-3,4- dihydroisoquinolin-1(2h)-one (10.1021/ACS.JMEDCHEM.2C00195 )
• 7UAS: discovery of potent orally bioavailable wd repeat domain 5 (wdr5) inhibitors using a pharmacophore-based optimization (10.1021/ACS.JMEDCHEM.2C00195 )